WEBVTT - Pfizer CEO Albert Bourla Talks Weight Loss Drugs

0:00:02.520 --> 0:00:07.640
<v Speaker 1>Bloomberg Audio Studios, podcasts, radio news.

0:00:08.000 --> 0:00:11.040
<v Speaker 2>We were preparing for this period of loss of exclusivity.

0:00:11.080 --> 0:00:13.840
<v Speaker 3>Is twenty six twenty eight. We did significant acquisitions.

0:00:14.000 --> 0:00:16.000
<v Speaker 2>One of them is in obesity, as you said, but

0:00:16.320 --> 0:00:21.680
<v Speaker 2>seeds them in oncology and nertech in Migraine, and this

0:00:21.760 --> 0:00:25.000
<v Speaker 2>portfolio is performing extremely well. This year will be approximately

0:00:25.040 --> 0:00:29.080
<v Speaker 2>ten billion dollars of sales growing double digit. Actually last

0:00:29.160 --> 0:00:32.760
<v Speaker 2>year twenty five and twenty six will continue growing at

0:00:32.800 --> 0:00:36.479
<v Speaker 2>a double digit. So I think after the twenty eight

0:00:36.600 --> 0:00:38.360
<v Speaker 2>period of ELOWI is where we are not going to

0:00:38.400 --> 0:00:41.680
<v Speaker 2>be a top line growth story. We will have exponential

0:00:41.760 --> 0:00:44.800
<v Speaker 2>growth that will be leading the industry.

0:00:45.360 --> 0:00:48.320
<v Speaker 1>So twenty it sounds like things improve, especially when you

0:00:48.320 --> 0:00:51.400
<v Speaker 1>think about the growth forecast there. But until that time,

0:00:52.159 --> 0:00:54.639
<v Speaker 1>you think about what you recently said at the fireside

0:00:54.680 --> 0:00:57.360
<v Speaker 1>chat earlier today, no plans for buybacks. You do have

0:00:57.440 --> 0:01:00.640
<v Speaker 1>these patent expirations coming up, and you don't expect to

0:01:00.640 --> 0:01:03.360
<v Speaker 1>put a GLP one on the market until twenty twenty eight.

0:01:03.520 --> 0:01:06.920
<v Speaker 1>So how do you keep investors engaged and attract new

0:01:06.959 --> 0:01:08.440
<v Speaker 1>investors during that period.

0:01:08.640 --> 0:01:11.319
<v Speaker 2>I think investors goes to see catalysts and this is

0:01:11.360 --> 0:01:14.200
<v Speaker 2>a year, but it's very rich in catalysts. We are

0:01:14.240 --> 0:01:18.039
<v Speaker 2>expecting redoubts of studies that they are significant. Two of

0:01:18.080 --> 0:01:21.720
<v Speaker 2>them actually will be in obesity with Metterira portfolio. One

0:01:21.760 --> 0:01:26.840
<v Speaker 2>it is the ultra long thirty days data, so the

0:01:27.280 --> 0:01:31.039
<v Speaker 2>mastly dozing data that will come in the first half

0:01:31.360 --> 0:01:34.240
<v Speaker 2>of this year. The other is the combination of zlp

0:01:34.319 --> 0:01:37.800
<v Speaker 2>one and amelin that also will come this year. But

0:01:37.880 --> 0:01:42.319
<v Speaker 2>there are many more. Rexfield, which is our Mama Mayloma drug,

0:01:43.480 --> 0:01:47.520
<v Speaker 2>has a redoubt that if successful, doubles the population that

0:01:48.240 --> 0:01:49.600
<v Speaker 2>we are going after.

0:01:51.040 --> 0:01:56.320
<v Speaker 3>The vaccine against the teak.

0:01:57.800 --> 0:02:02.040
<v Speaker 2>Thank you, which is a very big disease that there

0:02:02.120 --> 0:02:05.160
<v Speaker 2>is no vaccines so far, and that's the first one

0:02:05.280 --> 0:02:05.919
<v Speaker 2>lime disease.

0:02:07.040 --> 0:02:08.840
<v Speaker 3>So there are very rich in catalysts.

0:02:08.840 --> 0:02:11.000
<v Speaker 2>And of course we start a lot of facetree studies,

0:02:11.040 --> 0:02:14.800
<v Speaker 2>so investors I think are watching all of that, and

0:02:14.919 --> 0:02:16.959
<v Speaker 2>right now, of Alisa has a very low multiple, I

0:02:17.040 --> 0:02:20.960
<v Speaker 2>think we should start migrating towards the average multiple and

0:02:20.960 --> 0:02:23.720
<v Speaker 2>then exceeded as we go post our relain.

0:02:24.240 --> 0:02:27.320
<v Speaker 1>So plenty of catalyst coming up. Let's talk specifically about

0:02:27.400 --> 0:02:30.120
<v Speaker 1>met Sarah, because you want that hard fought getting more

0:02:30.440 --> 0:02:34.160
<v Speaker 1>with novo nor Risks certainly fun for someone who can

0:02:34.480 --> 0:02:37.639
<v Speaker 1>sent news to watch. When you think about the OBC market,

0:02:37.639 --> 0:02:40.120
<v Speaker 1>though you know you mentioned that this would be once monthly.

0:02:40.480 --> 0:02:43.680
<v Speaker 1>What do you see as the key differentiating factor when

0:02:43.720 --> 0:02:45.600
<v Speaker 1>it comes to what met Sarah is developing.

0:02:46.080 --> 0:02:48.280
<v Speaker 3>I think one it is the monthly dosing.

0:02:48.320 --> 0:02:52.280
<v Speaker 2>That's a very clear differentiation that creates significant advantages not

0:02:52.320 --> 0:02:58.440
<v Speaker 2>only in patient experience, but also in production and cost

0:02:58.440 --> 0:03:01.000
<v Speaker 2>of goods and all of that. The second is the

0:03:01.160 --> 0:03:04.119
<v Speaker 2>combination between a million and PDL one.

0:03:04.400 --> 0:03:06.560
<v Speaker 3>We are looking for superior.

0:03:06.080 --> 0:03:10.440
<v Speaker 2>Results than the current solos, So this combinations not only

0:03:10.440 --> 0:03:15.639
<v Speaker 2>would be a monthly but hopefully can deliver better way

0:03:15.880 --> 0:03:20.160
<v Speaker 2>loss place bodjusted and better tolerability, which are the two

0:03:20.200 --> 0:03:22.800
<v Speaker 2>things that are the achillte heels of the ZLP.

0:03:22.639 --> 0:03:23.400
<v Speaker 3>Ones right now.

0:03:23.919 --> 0:03:26.680
<v Speaker 2>And of course there is an oral portfolio of peptides

0:03:27.240 --> 0:03:30.959
<v Speaker 2>that is following. So it's a very complete, highly differentiated

0:03:31.000 --> 0:03:33.680
<v Speaker 2>portfolio in the hands of a company. But it is

0:03:34.000 --> 0:03:37.680
<v Speaker 2>very good in commercial activities, particularly when it comes to

0:03:38.600 --> 0:03:41.960
<v Speaker 2>products that they are very much consumer driven. I remind

0:03:42.000 --> 0:03:46.640
<v Speaker 2>you Viagra was a product that was behaving very similarly

0:03:46.640 --> 0:03:49.040
<v Speaker 2>like like the ZLP one.

0:03:49.320 --> 0:03:51.440
<v Speaker 1>Well, looking forward to those read outs as we get

0:03:51.440 --> 0:03:53.760
<v Speaker 1>deeper into twenty twenty six. I do want to talk

0:03:53.760 --> 0:03:56.000
<v Speaker 1>about M and A overall and what the strategy going

0:03:56.040 --> 0:03:58.920
<v Speaker 1>forward is, because last year you marked up to fifteen

0:03:58.960 --> 0:04:03.160
<v Speaker 1>billion dollars PERTY to help replenish the pipeline. Where are

0:04:03.200 --> 0:04:06.920
<v Speaker 1>you now? Do you feel pretty satisfied with the portfolio

0:04:06.920 --> 0:04:08.720
<v Speaker 1>at hand? Are you still looking for more deals.

0:04:09.040 --> 0:04:12.320
<v Speaker 2>I'm very satisfied with the portfolio hand, and we invested

0:04:12.360 --> 0:04:14.320
<v Speaker 2>almost ten of these fifteen billions, and then we have

0:04:14.360 --> 0:04:17.120
<v Speaker 2>five to six that are remaining and we plan to

0:04:17.160 --> 0:04:20.159
<v Speaker 2>invest them. We don't have to invest them, but we're

0:04:20.200 --> 0:04:23.880
<v Speaker 2>trying to make sure that we will find the right assets,

0:04:24.040 --> 0:04:29.080
<v Speaker 2>as we found with our oncology and obesity acquisitions.

0:04:29.120 --> 0:04:31.679
<v Speaker 1>And when it comes to cost cutting, you know, last

0:04:31.720 --> 0:04:34.120
<v Speaker 1>month you said that you're going to reinvest about five

0:04:34.240 --> 0:04:37.960
<v Speaker 1>hundred million dollars from savings from your cost cutting efforts

0:04:37.960 --> 0:04:39.960
<v Speaker 1>into R and D, and I'm curious, you know, where

0:04:39.960 --> 0:04:43.240
<v Speaker 1>do you see that investment going. Should we be focusing

0:04:43.240 --> 0:04:46.040
<v Speaker 1>on the obesity portfolio or there are other areas, Advisor

0:04:46.080 --> 0:04:46.359
<v Speaker 1>where you.

0:04:46.400 --> 0:04:48.520
<v Speaker 3>Plant it's let's start.

0:04:48.600 --> 0:04:52.440
<v Speaker 2>The on college portfolio right now absorbs approximately forty percent

0:04:52.480 --> 0:04:54.839
<v Speaker 2>of our investments and that will.

0:04:54.680 --> 0:04:58.480
<v Speaker 3>Continue going up. But the newcomers are the.

0:04:58.400 --> 0:05:02.440
<v Speaker 2>Obesity that, as I said, start with more than fifteen studies,

0:05:03.080 --> 0:05:06.200
<v Speaker 2>ten of them will be pivotal face thory studies. This

0:05:06.240 --> 0:05:09.840
<v Speaker 2>is a significant investment but also demonstrates how confident we

0:05:09.880 --> 0:05:11.679
<v Speaker 2>are in investing in these molecules.

0:05:12.200 --> 0:05:14.320
<v Speaker 1>And I do want to talk a little bit about

0:05:14.360 --> 0:05:16.960
<v Speaker 1>the political landscape as well, because you were the first

0:05:17.000 --> 0:05:20.120
<v Speaker 1>drug maker to strike a pricing deal with President Trump

0:05:20.560 --> 0:05:22.880
<v Speaker 1>last year. And I know that this is pretty much

0:05:22.880 --> 0:05:25.039
<v Speaker 1>an impossible question, but do you feel like you're out

0:05:25.080 --> 0:05:29.080
<v Speaker 1>of the woods when it comes to surprising terror threats,

0:05:29.160 --> 0:05:32.440
<v Speaker 1>price cuts, etc. What have your conversations with the White

0:05:32.440 --> 0:05:34.719
<v Speaker 1>House indicated so far, As you.

0:05:34.720 --> 0:05:37.960
<v Speaker 2>Said, is a very difficult question, but because of the

0:05:38.040 --> 0:05:42.440
<v Speaker 2>uncertainty that we know exist always, but we have created

0:05:42.800 --> 0:05:46.840
<v Speaker 2>very solid agreements and we have created a political environment

0:05:47.000 --> 0:05:50.880
<v Speaker 2>that there is good willingness.

0:05:49.760 --> 0:05:51.599
<v Speaker 3>From the White House to.

0:05:53.360 --> 0:05:57.880
<v Speaker 2>Respect and actually to help to help us with pricing

0:05:57.920 --> 0:06:01.480
<v Speaker 2>outside the US. They are helping us a lot actually

0:06:01.560 --> 0:06:04.679
<v Speaker 2>with pricing outside the US, with UK being the most

0:06:04.760 --> 0:06:05.680
<v Speaker 2>visible example.

0:06:05.880 --> 0:06:07.440
<v Speaker 3>I think Secretary.

0:06:07.080 --> 0:06:11.400
<v Speaker 2>Latnik as if the lot there in UK, they made

0:06:11.560 --> 0:06:15.720
<v Speaker 2>changes in their system that will invest way more in

0:06:15.720 --> 0:06:17.159
<v Speaker 2>innovative medicines than before.

0:06:18.200 --> 0:06:21.080
<v Speaker 3>So I'm optimistic that it's behind us, and.

0:06:21.080 --> 0:06:23.240
<v Speaker 1>I am curious. I mean, you think about how long

0:06:23.279 --> 0:06:25.640
<v Speaker 1>you've been at the Helm Advisor, when you compare and

0:06:25.640 --> 0:06:28.960
<v Speaker 1>contrast just the frequency of communications that you're having with

0:06:29.040 --> 0:06:33.159
<v Speaker 1>the Trump administration, how does that compare to past presidents

0:06:33.160 --> 0:06:33.839
<v Speaker 1>at this point.

0:06:34.279 --> 0:06:37.400
<v Speaker 2>Look, I was very close with the Trump administration in

0:06:37.520 --> 0:06:40.599
<v Speaker 2>the beginning. I was very close with the Biden administration

0:06:40.680 --> 0:06:43.880
<v Speaker 2>because we had to work together with COVID's. With Trump,

0:06:43.920 --> 0:06:46.960
<v Speaker 2>we work together to develop the vaccine. It was all

0:06:47.080 --> 0:06:50.159
<v Speaker 2>his baby, right. The operation was speed, but with Biden

0:06:50.400 --> 0:06:53.599
<v Speaker 2>was the period to scale it up to invest it.

0:06:54.480 --> 0:06:56.240
<v Speaker 3>I would say that we were.

0:06:56.120 --> 0:06:59.719
<v Speaker 2>Always very close to the Congress and to the White House.

0:07:00.320 --> 0:07:02.680
<v Speaker 3>I spent a lot of time in Washington myself a lot.

0:07:03.279 --> 0:07:05.520
<v Speaker 1>And given that you do spend so much time in Washington,

0:07:05.560 --> 0:07:08.480
<v Speaker 1>and again, given that you were the first drugmaker to

0:07:08.520 --> 0:07:11.440
<v Speaker 1>sign on to you know, these drug pricing deals, what

0:07:11.680 --> 0:07:14.640
<v Speaker 1>takeaways you know would you give to other CEOs who

0:07:14.640 --> 0:07:17.080
<v Speaker 1>are currently in conversation with the White House.

0:07:17.680 --> 0:07:20.800
<v Speaker 2>I think, engage, engage and discuss. I think I'm very

0:07:20.840 --> 0:07:22.720
<v Speaker 2>proud of what we did. I think what we did

0:07:23.200 --> 0:07:26.680
<v Speaker 2>opened the way for the entire industry. Probably already serventing

0:07:26.680 --> 0:07:28.080
<v Speaker 2>companies now have to sign up.

0:07:28.160 --> 0:07:29.160
<v Speaker 3>And it is the same.

0:07:28.920 --> 0:07:33.960
<v Speaker 2>Model, like we open and put to bed an issue

0:07:34.000 --> 0:07:37.200
<v Speaker 2>that was not sustainable, the big difference in pricing between

0:07:37.800 --> 0:07:44.560
<v Speaker 2>US and other originations, and now that it is probably

0:07:44.680 --> 0:07:47.440
<v Speaker 2>resolved in a gradual way because it's all the new products,

0:07:47.440 --> 0:07:50.320
<v Speaker 2>so it's a good deal and the other should engage

0:07:50.360 --> 0:07:52.000
<v Speaker 2>and and do it the same